This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer
Wei Wen1,5, Wei Liang1, Jun Wu2, Claudia M. Kowolik1, Ralf Buettner1, Anna Scuto1, Meng-Yin Hsieh2, Hao Hong3,4, Christine E. Brown3,4, Stephen J. Forman3, David Horne1, Robert Morgan6, Mark Wakabayashi5, Thanh H. Dellinger5, Ernest S. Han5, John H. Yim5*, Richard Jove1*#
1Department of Molecular Medicine, 2Department of Comparative Medicine, 3Department of Hematology/Hematopoietic Cell Transplantation, 4Department of Cancer Immunotherapeutics and Tumor Immunology, 5Department of Surgery, 6Department of Medical Oncology and Therapeutics Research Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd., Duarte, CA 91010 #Current Address: Vaccine & Gene Therapy Institute of Florida 9801 SW Discovery Way Port St. Lucie, Florida 34987 *Correspondence: John H. Yim, Department of Surgery, Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 Duarte Rd, Duarte, CA91010, Phone: 626-688-6072, Fax: 626-471-9212, Email: [email protected]. Richard Jove, Vaccine & Gene Therapy Institute of Florida, 9801 SW Discovery Way, Port St. Lucie, Florida 34987, email: [email protected] Running title: JAK1/STAT3 as a therapeutic target in ovarian cancer Key words: JAK1/STAT3, shRNA, peritoneal metastasis, ascites, late stage ovarian cancer Disclosure of Potential Conflicts of Interest: No potential conflicts of interest were disclosed. Grant Support: This work was supported by NIH grant R01 CA 115674-05 to R. Jove. The core facilities used in this study were supported by NCI p30 CA033572.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351(24):2519-29. 2. Romero I, Bast RC, Jr. Minireview: human ovarian cancer: biology, current
management, and paths to personalizing therapy. Endocrinology 2012;153(4):1593-602.
3. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11(10):719-25.
4. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. The lancet oncology 2006;7(11):925-34.
5. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature reviews Cancer 2005;5(5):355-66.
6. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer metastasis reviews 2012;31(1-2):143-62.
7. Lengyel E. Ovarian cancer development and metastasis. The American journal of pathology 2010;177(3):1053-64.
8. Ahmed N, Stenvers K. Getting to know ovarian cancer ascites: opportunities for targeted therapy- based translational research. Frontiers in Oncology 2013;3.
9. Morgan RJ, Jr., Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, et al. Epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(1):82-113.
10. Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Therapeutic advances in medical oncology 2010;2(3):175-87.
11. Landrum LM, Java J, Mathews CA, Lanneau GS, Jr., Copeland LJ, Armstrong DK, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013;130(1):12-8.
12. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9(3):167-81.
13. Blagden S, Gabra H. Promising molecular targets in ovarian cancer. Current opinion in oncology 2009;21(5):412-9.
14. Tagawa T, Morgan R, Yen Y, Mortimer J. Ovarian cancer: opportunity for targeted therapy. Journal of oncology 2012;2012:682480.
15. Han ES, Wakabayashi M, Leong L. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer. Current treatment options in oncology 2013;14(1):22-33.
16. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer 2009;9(6):415-28.
17. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013;12(8):611-29.
18. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5055-63.
19. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
20. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):945-54.
21. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer research 2004;64(10):3550-8.
22. Sansone P, Bromberg J. Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies. Journal of Clinical Oncology 2012;30(9):1005-14.
23. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013;12(8):611-29.
24. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecologic oncology 2000;79(1):67-73.
25. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415-21.
26. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11):798-809.
27. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98(3):295-303.
28. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10(1):105-15.
29. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11(6):595-6. 30. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Jr., Amin HM, Lai R, et al. The role
of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006;107(11):2730-40.
31. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British journal of cancer 1995;71(2):354-6.
32. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997;66(1):27-30.
33. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011;11:210.
34. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 2011;47(12):1883-9.
35. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nature protocols 2006;1(6):2643-9.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
36. Yang TT, Sinai P, Kain SR. An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Analytical biochemistry 1996;241(1):103-8.
37. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell 2009;16(6):487-97.
38. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011;25(3):538-50.
39. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011;71(21):6601-10.
40. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139(7):1315-26.
41. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer research 2009;69(17):6823-30.
42. Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, et al. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Molecular carcinogenesis 2010;49(2):114-20.
43. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013;15(7):848-62.
44. Sahai E. Illuminating the metastatic process. Nature reviews Cancer 2007;7(10):737-49.
45. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer research 1995;55(2):360-8.
46. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat 2013;2(2):e23828.
47. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6.
48. Bromberg J, Wang TC. Inflammation and Cancer: IL-6 and STAT3 Complete the Link. Cancer cell 2009;15(2):79-80.
49. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis. Cancer cell 2009;15(2):91-102.
50. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer. Cancer cell 2009;15(2):103-13.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077
Published OnlineFirst October 15, 2014.Mol Cancer Ther Wei Wen, Wei Liang, Jun Wu, et al. and metastasis in a peritoneal model of human ovarian cancerTargeting JAK1/STAT3 signaling suppresses tumor progression
Updated version
10.1158/1535-7163.MCT-14-0077doi:
Access the most recent version of this article at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1535-7163.MCT-14-0077